Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer

Clinical Cancer Research

Volumn 14, Issue 5, 2008, Pages 1464-1469

  Chiappori, Alberto A ^a   Haura, Eric ^a   Rodriguez, Francisco A ^a   Boulware, David ^a   Kapoor, Rachna ^a   Neuger, Anthony M ^a   Lush, Richard ^a   Padilla, Barbara ^a   Burton, Michelle ^a   Williams, Charles ^a   Simon, George ^a   Antonia, Scott ^a   Sullivan, Daniel M ^a   Bepler, Gerold ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; CARBOPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE FREE SURVIVAL; DRUG CLEARANCE; DRUG RESPONSE; DYSPNEA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPONATREMIA; HYPOXIA; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHIC PAIN; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; SENSORY NEUROPATHY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; SYNCOPE; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; SURVIVAL RATE;

EID: 40949108811     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1508     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Novello S, le Chevalier T. Is there a standard strategy in the management of locally advanced non-small cell lung cancer? Lung Cancer 2001;34 Suppl 4:S9-14.
3. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005;23:175-83.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
5. Carney DN, Hansen HH. Non-small-cell lung cancer - stalemate or progress ? N Engl J Med 2000;343:1261- 2.
6. Dy GK, Adjei AA. Novel targets for lung cancer therapy: part II. J Clin Oncol 2002;20:3016-28.
7. Dy GK, Adjei AA. Novel targets for lung cancer therapy: part I. J Clin Oncol 2002;20:2881-94.
8. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-6.
9. Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
10. Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med 2004;2:16.
11. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 2003;14:44-50.
12. Del Bufalo D, Di Castro V, Biroccio A, et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 2002;61:524-32.
13. Del Bufalo D, Di Castro V, Biroccio A, et al. Endothelin-1acts as a survival factor in ovarian carcinoma cells. Clin Sci (Lond) 2002;103 Suppl 48:302-5S.
14. Bagnato A, Salani D, Di Castro V, et al. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 1999;59:720-7.
15. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-89.
16. Yang X, Liu L, Qi H. [Study on endothelin-1 positive expression and quantitative analysis in lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi 1998;21:111-3.
17. Giaid A, Hamid QA, Springall DR, et al. Detection of endothelin immunoreactivity and mRNA in pulmonary tumours. J Pathol 1990;162:15-22.
18. Boldrini L, Gisfredi S, Ursino S, et al. Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. Eur J Cancer 2005;41:2828-35.
19. Arun C, DeCatris M, Hemingway DM, London NJ, O'Byrne KJ. Endothelin-1 is a novel prognostic factor in non-small cell lung cancer. Int J Biol Markers 2004;19:262-7.
20. Zhao YD, Springall DR, Hamid Q, Levene M, Polak JM. Localization and characterization of endothelin-1 receptor binding in the blood vessels of human pulmonary tumors. J Cardiovasc Pharmacol 1995;26 Suppl 3:S341-5.
21. Opgenorth TJ, Adler AL, Calzadilla SV, et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 1996;276:473-81.
22. Winn M, von Geldern TW, Opgenorth TJ, et al. 2,4-Diarylpyrrolidine-3- carboxylic acids-potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722. J Med Chem 1996;39:1039-48.
23. Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 2002;20:2171-80.
24. Zonnenberg BA, Groenewegen G, Janus TJ, et al. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 2003;9:2965-72.
25. Ryan CW, Vogelzang NJ, Vokes EE, et al. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res 2004;10:4406-11.
26. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-90.
27. Sottani C, Minoia C, D'Incalci M, Paganini M, Zucchetti M. High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol) in human plasma. Rapid Commun Mass Spectrom 1998;12:251-5.
28. Parise RA, Ramanathan RK, Zamboni WC, Egorin MJ. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003;783:231-6.
29. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
31. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-22.
32. Abbott Laboratories PPD, Research and Development. Atrasentan (ABT-627). Selective endothelin A (ETA) receptor antagonist. Investigator's brochure. Abbott Park (IL): Abbott Laboratories; 2004.
33. Rosano L, Spinella F, Di Castro V, Natali PG, Bagnato A. Therapeutic targeting of the endothelin A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan. J Cardiovasc Pharmacol 2003;44:S132-5.
34. Rosano L, Spinella F, Salani D, et al.Therapeutic targeting of the endothelin A receptor in human ovarian carcinoma. Cancer Res 2003;63:2447-53.
35. Salani D, Rosano L, Di Castro V, et al. ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro. Clin Sci (Lond) 2002;103 Suppl 48:318-21S.
36. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Proc Am Soc Clin Oncol 2005;23:LBA4.
37. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-94.
38. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
39. Treat J, Belani CP, Edelman MJ, et al. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC): update of the Alpha Oncology trial (A1-99002L) [abstract 7025]. Proc Am Soc Clin Oncol 2005;23:16S.